Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00043381
Status:
COMPLETED
Last Update Posted:
2013-01-24
First Post:
2002-08-08
Brief Title:
Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
Sponsor:
Astex Pharmaceuticals Inc
Organization:
Astex Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Open-label Phase III Trial of Decitabine 5-aza-2Deoxycytidine Versus Supportive Care in Adults With Advanced-stage Myelodysplastic Syndrome
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the safety and efficacy profiles of decitabine to those of supportive care in adults with advanced-stage myelodysplastic syndrome MDS
Detailed Description:
This experimental investigational study is intended to answer the question of whether decitabine is any better than supportive care alone in delaying progression worsening of the disease prolonging survival or improving the overall quality of life for MDS patients who are not candidates for bone marrow transplant BMT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None